Skip to main content

Table 7 Cell cycle alteration after treatment with bortezomib (Bor) and temozolomide (TMZ)

From: Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

Cell line Group Percentage of cells in different cell cycle phases (%)
G1 S G2
U251 20 nmol/L Bor 52.5 ± 3.99 35.98 ± 2.96 11.52 ± 1.66
200 μmol/L TMZ 54.45 ± 4.88 32.77 ± 3.25 12.78 ± 1.42
Bor + TMZ 78.31 ± 5.54 13.83 ± 1.58 7.86 ± 1.26
U87 20 nmol/L Bor 45.67 ± 2.99 30.73 ± 2.53 23.63 ± 1.88
200 μmol/L TMZ 66.44 ± 4.33 26.19 ± 2.20 7.37 ± 1.94
Bor + TMZ 81.40 ± 6.51 12.22 ± 1.54 6.42 ± 2.25